Ex-Biotechnology Center President Joins NC State University’s College of Management
Leslie Alexandre, who resigned in January as president and CEO of the North Carolina Biotechnology Center, has been named director of corporate relations for healthcare and life sciences at the North Carolina State University College of Management. In her new role, Alexandre will work to build strategic partnerships with healthcare and life science companies, emphasizing opportunities available through the college’s BioPharma Management Initiative and the national Center for Innovation Management Studies.
Alexandre, who started her new position Aug. 16, had headed the biotech center for four and a half years starting in August 2002. She also had recently served as adjunct professor in the management college’s Department of Management, Innovation and Entrepreneurship.
Before joining the biotech center, Alexandre was assistant director for industrial relations at the National Cancer Institute in Bethesda, Md., the first person to hold this position. From 1995 to 1998, Alexandre was vice president of corporate affairs and marketing for Oncormed, a provider of cancer-related genetic testing services in Gaithersburg, MD. Previously she held senior health policy positions for two US senators, and represented Electronic Data Systems and several Fortune 500 companies on health policy issues in Washington, DC.
Alexandre earned a bachelor's degree from the College of Letters and Science at the University of California, Davis; and a master's degree and a doctorate from the School of Public Health at the University of California, Los Angeles. She serves on numerous boards, including the North Carolina Biosciences Organization, the Council for Entrepreneurial Development, and the Advisory Council for the NC Museum of Natural Sciences. She is a founding member of the RTP Chapter of the Healthcare Businesswomen’s Association and a member of its advisory board.
Early-Stage Life Science VC Joins Prolog Ventures as Partner
Dan Broderick has joined Prolog Ventures, a St. Louis venture capital firm specializing in life science investments, as its fourth partner. Launched in 2001, Prolog invests in traditional healthcare opportunities as well as emerging areas such as nutrition, wellness, plant science, and enabling platforms.
Before joining Prolog, Broderick was a managing director at Mason Wells in Milwaukee, where he served on its board of directors and management committee and managed the firm’s first venture capital fund, the Mason Wells Biomedical Fund. Previously, he spent 18 years at the Mayo Clinic in Rochester, Minn., where he served as director of technology commercialization for 12 years and co-launched the clinic's corporate venture capital fund.
Through his career, Broderick been involved in the creation, financing, and growth of more than 20 venture-backed life science companies, most of them early-stage.
Broderick is a member of the board of directors of the National Venture Capital Association and the chair of its Research Committee; a trustee of both the Medical College of Wisconsin and the University of Wisconsin-Milwaukee Research Foundations; a member of the University of Minnesota Business Development Advisory Board; and a charter member of the venture capital advisory board of BioGenerator, a St. Louis nonprofit seed-capital investment fund.
Pittsburgh Life Sciences Greenhouse Elects Four New Members to Its Board of Directors
The public-private Pittsburgh Life Sciences Greenhouse, which assists life science companies in southwestern Pennsylvania, has appointed four professionals to its board of directors:
- Peter DeComo, chairman, CEO, and co-founder of Renal Solutions, a developer of renal dialysis systems for institutional and home use.
- John Kuzmishin, vice president of strategic business initiatives, University of Pittsburgh Medical Center.
- John Miclot, president and CEO of Respironics.
- Elizabeth Woo, vice president of biotechnology, Thermo Fisher Scientific.
DeComo previously served as chief operating officer of HemoTherapies, a San Diego startup company, and before that was senior vice president of the specialty pharmacy division for Olsten Health Services, now Accredo. Earlier, DeComo held senior positions in the healthcare industry, launching and commercializing specialized products and services to home patients. DeComo received his MS and BS degrees in healthcare and business management from the University of Pittsburgh.
Kuzmishin joined UPMC in 2004 and is a senior member of its strategic business initiatives group. Previously, Kuzmishin spent 15 years as a healthcare investment banker, most recently as head of the healthcare investment banking group at Robert W. Baird & Company from 1996 to 2004. Prior to Baird, he worked in the investment banking groups at Vector Securities International from 1990 to 1996, and Shearson Lehman Hutton from 1988 to 1990. He graduated Phi Beta Kappa with honors from the College of Wooster in 1988 earning a BA degree in business economics.
Miclot joined Respironics in 1998 when it acquired Healthdyne Technologies where he had served as senior vice president of sales and marketing from 1995 to 1998. At Respironics he has held a variety of positions, including group vice president of sleep disorders; senior vice president of sales, marketing and manufacturing; president of the homecare division; and chief strategic officer.
Woo overseesall aspects of sales to the biotechnology/biopharmaceutical market segment, including sales expenditures, business development, P&L, pricing and financial modeling, contracting, forecasting and territory development. Previously, she held positions as director of marketing, senior director of business development, senior director of technical marketing and product manager. She possesses a doctorate in pharmacology from George Washington University Medical Center and a BSc in biological sciences from Carnegie Mellon University.
Medical Research Lawyer Named to ScienceLawCenter at ASU
Robert Milligan, a shareholder at the Phoenix law firm Gallagher & Kennedy, has joined the advisory board for the Center for the Study of Law, Science and Technology at the Sandra Day O'Connor College of Law at Arizona State University. The center examines the challenges posed by new scientific discoveries and their technological applications. The board has more than 20 members, including leaders in the legal, technology, and science professions.
Milligan advises clients on medical research, antitrust issues, Medicare and Medicaid reimbursement, corporate and partnership law, and general business issues. He received a master of law degree in biotechnology and genomics at ASU this year. He received his law degree from DePaul University in 1980.
Angelica Therapeutics CEO Named Director of Strategic Diagnostics
Geoffrey Davis,the CEO of Angelica Therapeutics, has been named to the board of directors of Strategic Diagnostics, a Newark, Del., developer of antibody-based reagents and maker of analytical test kits. He will fill the term of Richard Defieux who is retiring from the board.
Davis was a founder and chief scientific officer of Abgenix, where he led the development of the company’s XenoMouse technology and helped develop Vectabix, a human monoclonal antibody for use in treating colorectal cancer, before the company was acquired last year by Amgen. Previously he was a faculty member at University of California, San Francisco, an investigator with the Howard Hughes Medical Institute, and director of immunology at Repligen and Cell Genesys.
Davis received his PhD in immunology from the University of California, San Francisco, and completed his postdoctoral work at Southwestern University.
Architectural Resources Cambridge Appoints Three New Associates
Sean Gaw, Jennifer Needham, and Jan Taylor have all been promoted to associate at ARC/Architectural Resources Cambridge, a Cambridge, Mass., architectural design firm specializing in biotechnology, educational, corporate, and athletic facilities.
Founded in 1969, ARC/Architectural Resources Cambridge College has carried out work for biotech companies such as Abbot, Genzyme, and Millipore, as well as for universities and colleges that include Boston College, Boston University, Duke, Harvard, Johnson & Wales, MIT, Princeton, Tufts, and the University of Massachusetts.